Endocrine therapy plus zoledronic acid in premenopausal breast cancer. - Wikidata - awgldk - TriplyDB

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

http://www.wikidata.org/entity/Q34943802

about

Bisphosphonates and other bone agents for breast cancer LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer 1,25-dihydroxyvitamin D3 treatment shrinks uterine leiomyoma tumors in the Eker rat model Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer Chemotherapy in Premenopausal Breast Cancer Patients Prevention and treatment of bone fragility in cancer patient Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence Collapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literature Human isoprenoid synthase enzymes as therapeutic targets Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients Bisphosphonates in breast cancer Plant sterols as anticancer nutrients: evidence for their role in breast cancer Zoledronic acid as an adjuvant therapy in patients with breast cancer: a systematic review and meta-analysis The sequential use of endocrine treatment for advanced breast cancer: where are we?Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline Osteonecrosis of the jaw during biyearly treatment with zoledronic acid for aromatase inhibitor associated bone loss in early breast cancer: A literature review Targeting tumor-stromal interactions in bone metastasis Combination of the c-Met inhibitor tivantinib and zoledronic acid prevents tumor bone engraftment and inhibits progression of established bone metastases in a breast xenograft model Discovery of Novel Allosteric Non-Bisphosphonate Inhibitors of Farnesyl Pyrophosphate Synthase by Integrated Lead Finding Molecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside?Clinical utilities of aromatase inhibitors in breast cancer Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myeloma A novel 3-D mineralized tumor model to study breast cancer bone metastasis Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study)13th st. Gallen international breast cancer conference 2013: primary therapy of early breast cancer evidence, controversies, consensus - opinion of a german team of experts (zurich 2013).AGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011.Update 2010 of the German AGO Recommendations for the Diagnosis and Treatment of Early and Metastatic Breast Cancer - Chapter A: Surgery, Pathology and Prognostic Factors, Adjuvant and Neoadjuvant Therapy, Adjuvant Radiotherapy Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.Exploiting the Metal-Chelating Properties of the Drug Cargo for In Vivo Positron Emission Tomography Imaging of Liposomal Nanomedicines.Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials.FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients.Stabilization of bone marrow infiltration by metastatic breast cancer with continuous doxorubicin Potential antitumor effects of nitrogen-containing bisphosphonate in hormone receptor negative breast cancer patients with bone metastases Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction.Clinical relevance and current challenges of research on disseminating tumor cells in cancer patients Do BIG1-98 and ZOFAST demand a change in guidelines for endocrine therapy?Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial.Prevention, diagnosis and treatment of osteoporosis following menopause induced due to oncological disease.

P2860

Q24203656-29435053-EBEA-469D-A9D6-DFEB2960D9E3 Q24240015-CEF42027-1998-4056-9884-3E3E70501F5D Q24597847-CD1B93CA-AAB1-4523-B9E8-AC6AE1F15FA4 Q24632275-E1DBAA98-755A-4983-992A-083F48779A8C Q24657145-36AF7400-6EAB-4A76-9D97-B6AD05FC9A88 Q26746212-BE421657-DDCD-4966-8161-535E4B7519D6 Q26774622-6E25D7CC-23B9-4129-BEB2-718D2017A3A0 Q26775765-09B2D608-C2DD-46D5-A140-82ABCD454B7A Q26795493-6476E443-2CB7-41B0-A1F2-7558968E008A Q26801348-45AD3BDD-0752-4301-BA65-B5C3B3FC60AE Q26822639-2AC3E053-558C-4EF2-AB00-E1A0C8FBFB87 Q26824762-1597E1B7-AD68-4AD6-BE9C-64F638D46AF6 Q26859326-880C5631-0DA1-40CB-948C-01FE70445345 Q26861053-6F08CD91-46D4-4E18-8A0E-C00D5BAB0FED Q26861745-91DB735D-875D-4E05-A623-7BDCD7AF958E Q26997396-08B71A49-E1D6-48CA-BD98-A8153FC220D5 Q27002430-C73DBD86-FB15-4794-A3BA-958128F62FBA Q27008336-04E9213F-7FAA-48C1-8B96-F0DA380F9046 Q27024561-B806A75F-A4A1-46D2-BE0D-F19BECAF779B Q27302940-9EED219C-D9E0-414F-A1A0-4CB59B7B7CEA Q27702178-CCFF6699-44A9-4329-9525-E9FC0F102AE7 Q28068956-7CFFB8C0-B287-41E0-8F27-BF5F3890A274 Q28081168-31FA2C02-E581-4F85-965F-7C419F211B9C Q28081996-3AA8E906-1E0F-44E2-939D-2406DB3399B8 Q28472598-D13386BE-D38C-4D05-B778-1A70E61FCBB3 Q28551320-9CF6AB0F-3045-441B-A315-FAEAA50FE558 Q30317570-C5BC4535-D39C-48A5-B3E2-521950079878 Q30318240-B303CE18-E242-4686-86E0-B49754336843 Q30318610-76CBD76F-6EB0-4992-BEE3-C60E7D3EC9FD Q30416847-246D91AC-447C-49BB-A8CF-49B4FB3C399B Q30829681-0A23E64B-8208-4458-A25A-BC9C13427C5F Q30976616-2223D2FF-E7CC-466B-81AA-0A73DAEA0C7E Q31150676-282C01DB-9E2E-4ED0-BF50-8D01E3CED0B0 Q33422353-6F748E27-997B-4F00-99FC-9FF6E2F874D1 Q33447971-65861C31-E90C-4BC6-96D5-31560685AE47 Q33531646-82448C0B-25A8-4669-8FD7-1F04EDBD3B3E Q33555492-3ADA10A5-F3D4-4598-B608-CEFF16B78CCA Q33555537-7CD6AB78-A3AA-4C10-8A6C-1FC8741D2394 Q33587199-020529B4-CD9D-478F-91E2-28FE27B33A27 Q33610328-1FD19F94-A56B-471B-9E4C-8C2249E136D2

P2860

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

http://www.wikidata.org/entity/Q34943802

description

2009 nî lūn-bûn

@nan

2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

@ast

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

@en

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

@nl

type

label

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

@ast

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

@en

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

@nl

prefLabel

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

@ast

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

@en

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

@nl

P1433

Q34943802-48E3A510-A79C-48B8-BA28-4ACE15BCCE8E

P1476

Q34943802-B6CD45C0-06DE-42DB-89C2-860CE3277FAC

P2093

Q34943802-10D3B8CD-0421-417C-B6F8-5DCBFDB17A18

Q34943802-3D71D80F-914C-425F-92D5-6FBC87133C5C

Q34943802-56180AA5-337B-42DF-8EE7-FA148C222487

Q34943802-5638FD04-2916-4DFB-930F-39450C70C156

Q34943802-5CADE593-E980-474E-B981-379CD7364001

Q34943802-6D0BD5BB-92DE-4267-8DBD-154CF9F41487

Q34943802-750F95B5-205B-4C0F-8396-884DC2D065B0

Q34943802-960AF8EC-6A8C-47BA-978C-6AFF9EFD9E47

Q34943802-AB0D4C0E-835D-4371-9C77-917D116AAA25

Q34943802-B5306A6C-4310-4912-A93B-1883862AF71B

P304

Q34943802-1FC6CDBB-A0DF-4DFA-9FC5-620DFD670359

P31

Q34943802-1CD4EA96-304A-4079-939D-DB8FA4979743

P356

Q34943802-A97C5ABA-ABC5-4AD5-B65D-5EE49B41ABBB

P407

Q34943802-4D84F1C3-4323-4E99-9CE0-F720322B0F84

P433

Q34943802-BAC0F94E-D373-406F-B31C-0F65E0A8C365

P478

Q34943802-145FE627-F10B-4AC1-9C43-F9F277D908A6

P50

Q34943802-1A821379-F259-4B5A-8A90-F6ABC4ADE012

Q34943802-A6367E90-25B1-41AD-B307-2BEE53BEAAEE

Q34943802-D5D4469C-2D4B-444A-8151-3317F873986B

P577

Q34943802-2E6FD676-4441-4C04-87CD-0742D9993B6C

P698

Q34943802-B60EC62F-5B5C-4B48-AE81-5075471FD258

P356

P1433

The New England Journal of Medicine

P1476

Endocrine therapy plus zoledronic acid in premenopausal breast cancer

@en

P2093

ABCSG-12 Trial Investigators

http://www.w3.org/2001/XMLSchema#string

Brigitte Mlineritsch

http://www.w3.org/2001/XMLSchema#string

C Marth

http://www.w3.org/2001/XMLSchema#string

Christian Menzel

http://www.w3.org/2001/XMLSchema#string

Christoph Tausch

http://www.w3.org/2001/XMLSchema#string

Ernst Rücklinger

http://www.w3.org/2001/XMLSchema#string

Gero Luschin-Ebengreuth

http://www.w3.org/2001/XMLSchema#string

Günther Steger

http://www.w3.org/2001/XMLSchema#string

Hellmut Samonigg

http://www.w3.org/2001/XMLSchema#string

Holger Eidtmann

http://www.w3.org/2001/XMLSchema#string

P304

679-691

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA0806285

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

360

http://www.w3.org/2001/XMLSchema#string

P50

Michael A Fridrik

P577

2009-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19213681

http://www.w3.org/2001/XMLSchema#string